{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:54:01Z","timestamp":1770504841751,"version":"3.49.0"},"reference-count":60,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"3","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2010]]},"DOI":"10.2133\/dmpk.25.223","type":"journal-article","created":{"date-parts":[[2010,7,2]],"date-time":"2010-07-02T06:14:04Z","timestamp":1278051244000},"page":"223-235","source":"Crossref","is-referenced-by-count":55,"title":["Assessment of Chimeric Mice with Humanized Liver as a Tool for Predicting Circulating Human Metabolites"],"prefix":"10.2133","volume":"25","author":[{"given":"Hidetaka","family":"Kamimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Mera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinya","family":"Souda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohichiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Iwatsubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Usui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.25.223_bb0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/019262339502300214","article-title":"The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies","volume":"23","author":"Wrighton","year":"1995","journal-title":"Toxicol. Pathol."},{"key":"10.2133\/dmpk.25.223_bb0010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/taap.2002.9440","article-title":"Drug metabolites in safety testing","volume":"182","author":"Baillie","year":"2002","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.2133\/dmpk.25.223_bb0015","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1021\/tx0602012","article-title":"Metabolites and safety: What are the concerns, and how should we address them?","volume":"19","author":"Smith","year":"2006","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.25.223_bb0020","series-title":"Guidance for Industry: Safety Testing of Drug Metabolites","article-title":"Food and Drug Administration","year":"2008"},{"key":"10.2133\/dmpk.25.223_bb0025","series-title":"Guidance for Industry: M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals","article-title":"Food and Drug Administration","year":"2010"},{"key":"10.2133\/dmpk.25.223_bb0030","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1021\/tx800432c","article-title":"Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development","volume":"22","author":"Leclercq","year":"2009","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.25.223_bb0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/bdd.660","article-title":"Metabolites in safety testing: metabolite identification strategies in discovery and development","volume":"30","author":"Nedderman","year":"2009","journal-title":"Biopharm. Drug Dispos."},{"key":"10.2133\/dmpk.25.223_bb0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/bdd.659","article-title":"Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations","volume":"30","author":"Zhu","year":"2009","journal-title":"Biopharm. Drug Dispos."},{"key":"10.2133\/dmpk.25.223_bb0045","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0041-008X(03)00128-5","article-title":"An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons","volume":"189","author":"Brandon","year":"2003","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.2133\/dmpk.25.223_bb0050","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S1359-6446(03)03019-8","article-title":"Strategies for using in vitro screens in drug metabolism","volume":"9","author":"Plant","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.2133\/dmpk.25.223_bb0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/tx8004086","article-title":"Predicting circulating human metabolites: how good are we?","volume":"22","author":"Anderson","year":"2009","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.25.223_bb0060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/tx8004357","article-title":"Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites","volume":"22","author":"Dalvie","year":"2009","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.25.223_bb0065","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0002-9440(10)63352-4","article-title":"Near-completely humanized liver in mice shows human-type metabolic responses to drugs","volume":"22","author":"Tateno","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.2133\/dmpk.25.223_bb0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/03602530601021340","article-title":"Application of chimeric mice with humanized liver for predictive ADME","volume":"39","author":"Katoh","year":"2007","journal-title":"Drug Metab. Rev."},{"key":"10.2133\/dmpk.25.223_bb0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tox.2007.11.012","article-title":"Chimeric mice with humanized liver","volume":"246","author":"Katoh","year":"2008","journal-title":"Toxicology"},{"key":"10.2133\/dmpk.25.223_bb0080","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1021\/tx900323a","article-title":"Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry","volume":"23","author":"Yamazaki","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.25.223_bb0085","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1126\/science.8108734","article-title":"Replacement of diseased mouse liver by hepatic cell transplantation","volume":"263","author":"Rhim","year":"1994","journal-title":"Science"},{"key":"10.2133\/dmpk.25.223_bb0090","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1073\/pnas.92.11.4942","article-title":"Complete reconstitution of mouse liver with xenogeneic hepatocytes","volume":"92","author":"Rhim","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.2133\/dmpk.25.223_bb0095","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1073\/pnas.95.1.310","article-title":"Liver repopulation with xenogenic hepatocytes in B and T celldeficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma","volume":"95","author":"Petersen","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.2133\/dmpk.25.223_bb0100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.510310126","article-title":"A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2-deficient mice","volume":"31","author":"Brown","year":"2000","journal-title":"Hepatology"},{"key":"10.2133\/dmpk.25.223_bb0105","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1053\/jhep.2001.23314","article-title":"Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus","volume":"33","author":"Dandri","year":"2001","journal-title":"Hepatology"},{"key":"10.2133\/dmpk.25.223_bb0110","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/90968","article-title":"Hepatitis C virus replication in mice with chimeric human livers","volume":"7","author":"Mercer","year":"2001","journal-title":"Nat. Med."},{"key":"10.2133\/dmpk.25.223_bb0115","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nbt1326","article-title":"Robust expansion of human hepatocytes in Fah-\/- \/Rag2-\/-\/Il2rg-\/- mice","volume":"25","author":"Azuma","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.2133\/dmpk.25.223_bb0120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bbrc.2008.09.124","article-title":"Establishment of a humanized model of liver using NOD\/Shi-scid IL2Rgnull mice","volume":"377","author":"Suemizu","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.2133\/dmpk.25.223_bb0125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0092-8674(91)90615-6","article-title":"Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene","volume":"66","author":"Sandgren","year":"1991","journal-title":"Cell"},{"key":"10.2133\/dmpk.25.223_bb0130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","article-title":"Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs","volume":"53","author":"Bertilsson","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.25.223_bb0135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","article-title":"Polymorphism of human cytochrome P450 enzymes and its clinical impact","volume":"41","author":"Zhou","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"10.2133\/dmpk.25.223_bb0140","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00228-006-0250-8","article-title":"Jaehde, u. and Fuhr, u.: Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping","volume":"63","author":"Frank","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.25.223_bb0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2125.1983.tb01528.x","article-title":"Genetically determined oxidation capacity and the disposition of debrisoquine","volume":"15","author":"Sloan","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.25.223_bb0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.1978.tb01594.x","article-title":"The disposition of debrisoquine in hypertensive patients","volume":"5","author":"Silas","year":"1978","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.25.223_bb0155","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/00498257609151653","article-title":"Metabolism of debrisoquine sulphate in rat, dog and man","volume":"6","author":"Allen","year":"1976","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.25.223_bb0160","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0022-3565(24)36943-5","article-title":"Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes","volume":"282","author":"Masubuchi","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.25.223_bb0165","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1124\/mol.60.6.1260","article-title":"The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4 on the disposition of debrisoquine in the mouse","volume":"60","author":"Corchero","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.2133\/dmpk.25.223_bb0170","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/jps.20783","article-title":"In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver","volume":"96","author":"Katoh","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.2133\/dmpk.25.223_bb0175","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1124\/dmd.104.001347","article-title":"Expression of human cytochromes P450 in chimeric mice with humanized liver","volume":"32","author":"Katoh","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.25.223_bb0180","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/01213011-199912000-00004","article-title":"Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes","volume":"9","author":"Dal\u00e9n","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.2133\/dmpk.25.223_bb0185","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/cpt1974154424","article-title":"Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man","volume":"15","author":"Breckenridge","year":"1974","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.25.223_bb0190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0163-7258(96)00140-4","article-title":"Human P450 metabolism of warfarin","volume":"73","author":"Kaminsky","year":"1997","journal-title":"Pharmacol. Ther."},{"key":"10.2133\/dmpk.25.223_bb0195","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0006-2952(97)00304-3","article-title":"Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R-and S-warfarin enantiomers","volume":"54","author":"Yamazaki","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.25.223_bb0200","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/FTD.0b013e31805c956e","article-title":"Simultaneous determination of warfarin enantiomers and its metabolite in human plasma by column-switching high-performance liquid chromatography with chiral separation","volume":"29","author":"Uno","year":"2007","journal-title":"Ther. Drug Monit."},{"key":"10.2133\/dmpk.25.223_bb0205","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/00498250500307251","article-title":"Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver","volume":"35","author":"Nishimura","year":"2005","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.25.223_bb0210","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1124\/dmd.108.022830","article-title":"CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver","volume":"36","author":"Inoue","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.25.223_bb0215","series-title":"Handbook of PK\/PD examination technique","first-page":"333","author":"Kamimura","year":"2009"},{"key":"10.2133\/dmpk.25.223_bb0220","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3109\/00498258409151460","article-title":"Disposition and metabolism of amosulalol hydrochloride, a new combined alpha- and beta- adrenoceptor blocking agent, in rats, dogs and monkeys","volume":"14","author":"Sasaki","year":"1984","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.25.223_bb0225","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1248\/bpb.30.1580","article-title":"Pharmacokinetics and metabolism of an \u03b1, \u03b2-blocker, amosulalol hydrochloride, in mice: biliary excretion of carbamoyl glucuronide","volume":"30","author":"Suzuki","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"10.2133\/dmpk.25.223_bb0230","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/00498258509045012","article-title":"Metabolism of amosulalol hydrochloride in man: quantitative comparison with laboratory animals","volume":"15","author":"Kamimura","year":"1985","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.25.223_bb0235","first-page":"201","article-title":"Relative contribution of CYP2D6 and CYP3A4 to the metabolism of amosulalol, an \u03b1 and \u03b2 adrenoceptor blocker, in individual human liver microsomes","volume":"37","author":"Mera","year":"2005","journal-title":"Drug Metab. Rev. Suppl."},{"key":"10.2133\/dmpk.25.223_bb0240","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1124\/dmd.105.005157","article-title":"Expression of human phase II enzymes in chimeric mice with humanized liver","volume":"33","author":"Katoh","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.25.223_bb0245","series-title":"Prediction of human in vivo metabolism using chimeric mice with humanized livers: Impact of metabolic activity derived from original mouse hepatocytes and extrahepatic organs on interpretation","author":"Kitamura","year":"2008"},{"key":"10.2133\/dmpk.25.223_bb0250","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2125.1982.tb01430.x","article-title":"Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver","volume":"13","author":"Kahn","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.25.223_bb0255","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0090-9556(25)08754-9","article-title":"Characteristics of warfarin hydroxylation catalyzed by human liver microsomes","volume":"17","author":"Rettie","year":"1989","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.25.223_bb0260","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/0006-2952(85)90027-9","article-title":"Maintenance of cytochrome P-450 in cultured adult human hepatocytes","volume":"34","author":"Guillouzo","year":"1985","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.25.223_bb0265","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/00498250210128675","article-title":"Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells","volume":"32","author":"Rod\u0155iguez-Antona","year":"2002","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.25.223_bb0270","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2133\/dmpk.17.93","article-title":"Drug transporters: their role and importance in the selection and development of new drugs","volume":"17","author":"Mizuno","year":"2002","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.25.223_bb0275","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-9556(24)15299-3","article-title":"Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats","volume":"27","author":"Liu","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.25.223_bb0280","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/00498250050200104","article-title":"Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes","volume":"30","author":"Emoto","year":"2000","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.25.223_bb0285","unstructured":"Gibaldi, M. and Perrier, D.: Pharmacokinetics. New York, Marcel Dekker, Inc., Second Edition, Revised and Expanded, pp. 319\u2013353."},{"key":"10.2133\/dmpk.25.223_bb0290","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2133\/dmpk.24.153","article-title":"Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver","volume":"24","author":"Inoue","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.25.223_bb0295","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/clpt.1984.201","article-title":"Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses","volume":"36","author":"Nakashima","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.25.223_bb0300","first-page":"291","article-title":"Application of chimeric mice with humanized liver for study of human-specific drug metabolism","volume":"41","author":"Bateman","year":"2009","journal-title":"Drug Metab. Rev. Suppl."}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715300264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715300264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T14:01:29Z","timestamp":1740232889000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715300264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"alternative-id":["S1347436715300264"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.25.223","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2010]]}}}